Venthera

Venthera is a biotechnology company developing treatments for venous and lymphatic malformations as well as congenital disorders. They have developed a topical PI3K inhibitor to safely and effectively treat these lesions at the source. Venthera’s lead product, VT30 Topical Gel, is designed to target the correct tissue—the network of malformed vessels beneath the skin—and features a gel formulation optimized for skin penetration.